Ultrasensitive plasma ctDNA KRAS assay for detection, prognosis, and assessment of therapeutic response in patients with unresectable pancreatic ductal adenocarcinoma.
about
Ultrasensitive plasma ctDNA KRAS assay for detection, prognosis, and assessment of therapeutic response in patients with unresectable pancreatic ductal adenocarcinoma.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh
2017年學術文章
@zh-hant
name
Ultrasensitive plasma ctDNA KR ...... creatic ductal adenocarcinoma.
@en
Ultrasensitive plasma ctDNA KR ...... creatic ductal adenocarcinoma.
@nl
type
label
Ultrasensitive plasma ctDNA KR ...... creatic ductal adenocarcinoma.
@en
Ultrasensitive plasma ctDNA KR ...... creatic ductal adenocarcinoma.
@nl
prefLabel
Ultrasensitive plasma ctDNA KR ...... creatic ductal adenocarcinoma.
@en
Ultrasensitive plasma ctDNA KR ...... creatic ductal adenocarcinoma.
@nl
P2093
P2860
P356
P1433
P1476
Ultrasensitive plasma ctDNA KR ...... creatic ductal adenocarcinoma.
@en
P2093
Benny V Jensen
Eric A Collisson
Jennifer A Geis
Julia S Johansen
Kirstine L Hermann
Mark G Erlander
Victoria M Raymond
P2860
P304
97769-97786
P356
10.18632/ONCOTARGET.22080
P407
P577
2017-10-26T00:00:00Z